Surveys on patients’ experiences
During the COVID-19 situation, different areas such as Eurordis and Global Rheumatology Alliance are during surveys to monitor patients experiences with COVID-19.
The Rare Barometer Survey on rare diseases is active until 17 May, 2020.
It will enable EURORDIS to measure how the virus is affecting rare disease patients’ lives and give us the possibility to communicate facts and figures to decision-makers, so that people living with a rare disease are not left behind when handling the crisis.
The Global Rheumatology Alliance is inviting patients with rheumatological diseases (like scleroderma) to complete a survey regarding their experiences with Covid-19. You do not need to have had Covid-19 to participate, but your answers will help the rheumatology community.
news & events
Watch our highlights video showing some of our great achievements in 2022.
Are you living with diffuse scleroderma?
Would you like to be involved in a clinical study testing a new investigational drug for use in Diffuse Scleroderma?
If so, you may be eligible to take part in the DECODE Scleroderma Study
FESCA is proud to be a partner of a the new This is Living campaign launched last month by Boehringer Ingelheim.